Fundraising FoxEnavate Sciences
Growth equityMenlo Park · Growth · 8 people tracked
Find your way into Enavate Sciences
Sign up to see every warm intro you have to Enavate Sciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Enavate Sciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Enavate Sciences focuses on investing in and supporting the growth of innovative life sciences companies, including therapeutic and enabling technology businesses with potential to transform patient care and address unmet medical needs. It evaluates a broad range of therapeutic areas across both pre-clinical and clinical stage companies, emphasizing growth potential. Positioning itself as a company-building partner of choice for life sciences companies and their existing investors, the firm provides significant capital, personalized attention, and strategic growth support to help each company realize its full potential.
Source: firm website, verified Nov 8, 2026.
Team · 8 people
from the firm's website & public directories
Amar Patel is a Principal at Enavate Sciences, where he works on executing investment opportunities and supporting partner companies operationally and strategically. He was previously an investor on the biotech team at Longitude Capital and began his career in the Healthcare Investment Banking group at J.P. Morgan. He holds a B.A. in Neuroscience from the University of Pennsylvania and a B.S. in Finance from Wharton, completed through the Roy and Diana Vagelos Program in Life Sciences and Management.
Christopher Lo is a Vice President on the investment team at Enavate Sciences, where he works on prospecting, due diligence, and supporting partner companies. He previously evaluated investments and worked on developing medicines at Roivant Sciences, and contributed to clinical development of gene therapies for rare diseases at Aruvant Sciences. He holds a B.A.S. in Bioengineering and a B.S. in Economics and Statistics from the University of Pennsylvania's Jerome Fisher Program in Management & Technology and Wharton.
Edd Fleming, M.D. is Executive Vice President, Commercialization at Enavate Sciences, where he works on origination, diligence, and selection of investments and supports portfolio companies with strategic planning, governance, partnerships, and commercialization. He spent 26 years at McKinsey and Company as a senior partner in the Life Science practice, later leading the firm's R&D practice, after earlier serving as a board-certified pulmonologist and critical care physician at UCSF. He holds an A.B. in Chemistry from Harvard College and an M.D. from Vanderbilt Medical School.
James Boylan is a health care executive with nearly three decades of experience who leads Enavate Sciences as CEO. He previously served as President and Head of Investment Banking at SVB Leerink and was a Managing Director at Merrill Lynch, working with hundreds of life sciences and biotechnology companies.
Jim Momtazee is Managing Partner of Patient Square Capital and serves as Chairman of the Board of Directors of Enavate Sciences.
Monika Juneja is the Business Manager at Enavate Sciences, where she handles the firm's operations from origination to execution and works on business processes and strategic initiatives. She previously spent six years at Credit Suisse, most recently as Group Operations Generalist supporting the COO for the Financial Sponsors and Media & Telecom groups, and earlier launched the high-end retail division at Shane of New York after starting her career in hotel sales and marketing. She holds an MA in Sociology from the University of New Delhi and a BA in Sociology from Jesus and Mary College, India.
Robert Glassman, M.D., is Executive Vice President, Search & Evaluation at Enavate Sciences, where he works on sourcing and evaluating investments and supports portfolio company growth and governance. He previously was a venture partner in public equity and private equity partner at OrbiMed Advisors, and spent over seventeen years in health care investment banking at Credit Suisse (as Vice Chairman of Global Health Care Investment Banking), Merrill Lynch, and Bank of America. Earlier he led health care investments at Merrill Lynch Global Private Equity, consulted at McKinsey & Company, practiced as a hematologist-oncologist, and holds an A.B. from Harvard College and an M.D. from Harvard Medical School.
Sai Abhishek is a Vice President at Enavate Sciences, where he works on sourcing, due diligence, investment execution, and supporting partner companies. He previously served as Director of Portfolio Strategy and Business Development at Code Biotherapeutics and was an investor on the healthcare team at New Enterprise Associates focused on biopharma, before which he began his career in healthcare investment banking at Credit Suisse. He holds a B.S. in Economics from the Wharton School at the University of Pennsylvania.
What they invest in
from 16 of 16 portfolio companiesBiotech ×14Healthtech ×13Medical Devices ×5AI & Machine Learning ×3Deep Tech ×2Digital Health ×2Crypto & Web3 ×1Developer Tools ×1
HQs:United States×9
Investments · 16 tracked
founders shown can be your intro pathBy year:2023 · 12017 · 12 dated
Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.
BiotechHealthtechMedical Devices
Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)
Co-investorsAtlas VentureOrbiMedRA CapitalViking Global
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Healthcare Investments+6 more
Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.
BiotechHealthtechCambridge, US
Schuetz Thomas(Executive Officer, Director)inErrik Anderson(Executive Officer, Director)inThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNeil Lerner(Senior Vice President, Chief Accounting Officer)in
Co-investorsAlumni VenturesBioBritF-Prime CapitalForesite CapitalGV (Google Ventures)OrbiMed+4 more
Immunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer.
BiotechHealthtechExton, US
Scott K. Dessain(Executive Officer, Director)inDennis H Giesing(Executive Officer)inCorleen Roche(Executive Officer)inMichael J Morin(Executive Officer)Purnanand Sarma(Executive Officer, Director)inGeorge Hobbs(Executive Officer)
Co-investorsBioAdvanceDelaware Crossing Investor GroupEvolution VC PartnersMilitia Hill VenturesPivotal Life SciencesRobin Hood Ventures+1 more
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Co-investorsDelos CapitalLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersPivotal Life SciencesQuan Capital+4 more
Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Michael Tolentino(Executive Officer, Director)inMohamed A. Genead(Chairman & CEO)inDavid Callanan(Executive Officer)inDerek Kunimoto(Executive Officer)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in
Co-investorsJeito CapitalLongitude CapitalCatalio Capital Management, LPOrbiMedAvoro Capital AdvisorsDigitalis Ventures+1 more
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+7 more
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)inSrinivas Akkaraju(Director)
Co-investorsAscenta CapitalLongitude CapitalSamsara BioCapitalF-Prime Capital
Ambros Therapeutics is a therapeutics company.
BiotechHealthtechSan Diego, US
Joseph (Jay) Hagan(President and Chief Executive Officer)
Co-investorsLifeSci Venture PartnersRA CapitalBAM ElevateJanus Henderson InvestorsPatient Square Capital
Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.
BiotechDigital HealthHealthtechMedical Devices
Travis Murdoch, M.D.(Chief Executive Officer and Board Director)in
Co-investorsAndreessen HorowitzFrazier Life SciencesOrbiMedForbion
BridgeBio Oncology develops cancer therapies targeting tumors driven by RAS and PI3Kα signaling, using RAS signaling biology to design drugs that inhibit RAS-driven PI3K activation and a range of KRAS mutants in both their active (ON) and inactive (OFF) states.
BiotechHealthtech
Co-investorsAisling CapitalWellington Management
Camp4 is a biotechnology company focused on genetic research and neurology, leveraging expertise in genomics and neuroscience for therapeutic development.
AI & Machine LearningBiotech
Leonard Zon(Founder)Richard Young(Founder)
BoardChristopher Walsh, MD, PhD(Scientific Advisor)
Co-investors5AM VenturesAndreessen HorowitzFlucas VenturesNorthpond Ventures
Graviton offers an AI model trained on blockchain technology, including Solidity, to help developers build Web3 decentralized applications (dApps) from a prompt.
AI & Machine LearningCrypto & Web3Developer Tools
Co-investorsBlueYard CapitalPontifax Venture Capital
Graviton develops immunomodulatory therapies for patients with fibrotic, autoimmune, and central nervous system diseases.
AI & Machine LearningBiotechDeep TechHealthtechNew York, US
Samuel Waksal(Founder & CEO)Steven Gordon(Executive Officer, Director)
BoardPhilip Barach(Director)Richard Giroux(Director)
Co-investorsInnova Capital Partners, LLCPontifax Venture Capital
Patient Square Capital is a healthcare investment firm managing $19 billion in assets that partners with growth-oriented companies developing products, services, and technologies to improve patient health outcomes.
Healthtech
Co-investorsBCI
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)inScott Byrd(Executive Officer, Director)in
Co-investorsFrazier Life SciencesMonograph Capital PartnersMSA NovoPICUS CAPITALSanofi VenturesSV Health Investors+5 more
Exits · 6
5 IPOs · 1 acquisitionsSionna TherapeuticsNASDAQ: SIONUpstream BioNASDAQ: UPBCompass TherapeuticsNASDAQ: CMPXImmunomeNASDAQ: IMNMZenas BiopharmaNASDAQ: ZBIOAmbros Therapeuticsacq. by Werewolf Therapeutics
Portfolio news
latest coverage across their companiesImmunome · stocktitan.net · Aug 14, 2026
Upstream Bio · stocktitan.net · Aug 11, 2026
Braveheart · en.oninvest.com · Aug 6, 2026
Aviceda Therapeutics · forgeglobal.com · May 14, 2026
Ambros Therapeutics · cooley.com · Dec 16, 2025
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Zenas Biopharma | 7.2% | $17.00 | Sep 2024 | $48.9M |
| Upstream Bio | 4.2% | $17.00 | Oct 2024 | $36.7M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Enavate Sciences made?
- Enavate Sciences has 16 tracked investments, 6 of which have exited.
- What stage does Enavate Sciences invest at?
- Enavate Sciences invests at the Growth stage.
- What sectors does Enavate Sciences focus on?
- Enavate Sciences focuses on Biotech, Healthtech, Longevity, Medical Devices.
- Where is Enavate Sciences located?
- Enavate Sciences is headquartered in Menlo Park, US.
Images
